It has been known for decades that HER2 is gene-amplified in 20–25% of breast cancer patients, and is associated with a more aggressive phenotype and poorer prognosis3, making it an appealing target for both diagnosis and therapy. This evidence concerns the gene ERBB2 and breast cancer.